Product Details

Veramox-B Syrup combines a broad-spectrum antibiotic with a mucolytic agent for the management of bacterial respiratory infections accompanied by excessive mucus. Specifically, each 5ml delivers Amoxycillin Trihydrate equivalent to 250mg Amoxycillin together with Bromhexine Hydrochloride 8mg. As a result, it offers combined antibacterial action and mucus-clearing support in a single formulation.

The syrup combines:

• Amoxycillin Trihydrate IP (equivalent to Amoxycillin 250mg per 5ml) – A broad-spectrum, beta-lactam antibiotic of the aminopenicillin class that inhibits bacterial cell wall synthesis. Consequently, it disrupts the structural integrity of susceptible bacteria, leading to cell lysis and death.
• Bromhexine Hydrochloride IP (8mg per 5ml) – A mucolytic agent that breaks down mucopolysaccharide fibres in respiratory secretions. As a result, it reduces mucus viscosity, making it easier to clear from the airways and complementing the antibacterial action.

Physicians prescribe Veramox-B for bacterial respiratory tract infections accompanied by thick, difficult-to-clear mucus, such as bronchitis with a bacterial component. In addition, its combined formula addresses both the underlying infection and the associated mucus congestion in a single syrup. Because of this profile, Veramox-B suits general practice and paediatric settings managing respiratory infections with mucus involvement.

Key Features:

• Overall, this combination formulation guarantees pharmaceutical-grade purity across both actives
• Additionally, the dual-action formula addresses infection and mucus congestion together
• Furthermore, each 5ml delivers precise, validated dosage accuracy at 250mg + 8mg
• Notably, rigorous quality testing backs every stage of manufacturing
• Beyond that, light-protected bottle packaging preserves syrup stability
• Ultimately, a reliable supply chain suits bulk distribution to hospitals, clinics, and pharmacies